AccuMed buys up remaining share of Oncometrics
This article was originally published in Clinica
Executive Summary
AccuMed is to acquire the remaining one-third of Xillix' subsidiary, Oncometrics Imaging, that it does not already own. Chicago-based AccuMed obtained the two-thirds share in Oncometrics in the middle of 1996 to commercialise its quantitative microscopy imaging technology and the results of research into early cancer detection (see Clinica No 714, p 12). The terms of the recent transaction were not disclosed.